The market size value per capita in Belarus for hormones in dosage, excluding contraceptives and antibiotics, showed a steady increase from 2013 to 2021. The sharpest rise was between 2019 and 2021, with annual growth rates of 6.12% and 6.0%, respectively. However, in 2022, there was a notable decline of 8.07%, followed by a modest recovery of 1.15% in 2023, reaching a value of $5.3. Over the last five years, the compound annual growth rate (CAGR) was 1.11%, indicating stable but slow growth.
In the future, keep an eye on regulatory changes and health trends in Belarus, which could impact market development. Additionally, potential economic fluctuations and healthcare policies should be monitored as they may influence market dynamics and per capita spending on hormones in dosage.
